ENO2 and cardiac arrest: Our findings are consistent with large registry-based analyses and randomized trials, such as the TTM trial (Nielsen et al. 2013) and the TTM2 trial (Dankiewicz et al. 2021), which have demonstrated the prognostic value of biomarkers, including NSE, across heterogeneous post-cardiac arrest populations [15,16].